Alirocumab after Acute Coronary Syndrome

Nick S.R. Lan; Bu B. Yeap; P. Gerry Fegan

doi:10.1056/NEJMc1902955

Alirocumab after Acute Coronary Syndrome

Nick S.R. Lan, Bu B. Yeap, P. Gerry Fegan

Research output: Contribution to journal › Letter › peer-review

2 Citations (Web of Science)

Abstract

To the Editor: In the ODYSSEY OUTCOMES trial, Schwartz et al. (Nov. 29 issue)(1) report that the proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitor alirocumab could reduce the risk of recurrent ischemic cardiovascular events in patients who have had an acute coronary syndrome and are receiving intensive statin therapy. However, because less than 3% of these patients were receiving ezetimibe in addition to statin therapy, the trial might not support the use of alirocumab in similar patients in clinical practice. According to the latest guideline on the management of cholesterol,(2) ezetimibe should be added to statin therapy (given at the . . .

Original language	English
Pages (from-to)	2075-2076
Number of pages	2
Journal	The New England Journal of Medicine
Volume	380
Issue number	21
DOIs	https://doi.org/10.1056/NEJMc1902955
Publication status	Published - 23 May 2019

Access to Document

10.1056/NEJMc1902955

Cite this

@article{7494d8cf4b7d4cbb82541e07cc4190ba,

title = "Alirocumab after Acute Coronary Syndrome",

abstract = "To the Editor: In the ODYSSEY OUTCOMES trial, Schwartz et al. (Nov. 29 issue)(1) report that the proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitor alirocumab could reduce the risk of recurrent ischemic cardiovascular events in patients who have had an acute coronary syndrome and are receiving intensive statin therapy. However, because less than 3% of these patients were receiving ezetimibe in addition to statin therapy, the trial might not support the use of alirocumab in similar patients in clinical practice. According to the latest guideline on the management of cholesterol,(2) ezetimibe should be added to statin therapy (given at the . . .",

author = "Lan, {Nick S.R.} and Yeap, {Bu B.} and Fegan, {P. Gerry}",

year = "2019",

month = may,

day = "23",

doi = "10.1056/NEJMc1902955",

language = "English",

volume = "380",

pages = "2075--2076",

journal = "The New England Journal of Medicine",

issn = "0028-4793",

publisher = "MASSACHUSETTS MEDICAL SOC",

number = "21",

}

TY - JOUR

T1 - Alirocumab after Acute Coronary Syndrome

AU - Lan, Nick S.R.

AU - Yeap, Bu B.

AU - Fegan, P. Gerry

PY - 2019/5/23

Y1 - 2019/5/23

N2 - To the Editor: In the ODYSSEY OUTCOMES trial, Schwartz et al. (Nov. 29 issue)(1) report that the proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitor alirocumab could reduce the risk of recurrent ischemic cardiovascular events in patients who have had an acute coronary syndrome and are receiving intensive statin therapy. However, because less than 3% of these patients were receiving ezetimibe in addition to statin therapy, the trial might not support the use of alirocumab in similar patients in clinical practice. According to the latest guideline on the management of cholesterol,(2) ezetimibe should be added to statin therapy (given at the . . .

AB - To the Editor: In the ODYSSEY OUTCOMES trial, Schwartz et al. (Nov. 29 issue)(1) report that the proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitor alirocumab could reduce the risk of recurrent ischemic cardiovascular events in patients who have had an acute coronary syndrome and are receiving intensive statin therapy. However, because less than 3% of these patients were receiving ezetimibe in addition to statin therapy, the trial might not support the use of alirocumab in similar patients in clinical practice. According to the latest guideline on the management of cholesterol,(2) ezetimibe should be added to statin therapy (given at the . . .

UR - http://www.scopus.com/inward/record.url?scp=85066493960&partnerID=8YFLogxK

U2 - 10.1056/NEJMc1902955

DO - 10.1056/NEJMc1902955

M3 - Letter

C2 - 31116931

AN - SCOPUS:85066493960

SN - 0028-4793

VL - 380

SP - 2075

EP - 2076

JO - The New England Journal of Medicine

JF - The New England Journal of Medicine

IS - 21

ER -

Alirocumab after Acute Coronary Syndrome

Abstract

Access to Document

Other files and links

Fingerprint

Cite this